Cite
Effects of age and disease duration on the efficacy and safety of iGlarLixi in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan‐O‐AP and LixiLan‐L‐CN trials.
MLA
Yang, Wenying, et al. “Effects of Age and Disease Duration on the Efficacy and Safety of IGlarLixi in Asian People with Type 2 Diabetes: A Post Hoc Analysis of the LixiLan‐O‐AP and LixiLan‐L‐CN Trials.” Diabetes, Obesity & Metabolism, vol. 26, no. 4, Apr. 2024, pp. 1197–206. EBSCOhost, https://doi.org/10.1111/dom.15414.
APA
Yang, W., Guo, X., Lauand, F., Li, L., Fang, H., Du, Q., & Kang, L. (2024). Effects of age and disease duration on the efficacy and safety of iGlarLixi in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan‐O‐AP and LixiLan‐L‐CN trials. Diabetes, Obesity & Metabolism, 26(4), 1197–1206. https://doi.org/10.1111/dom.15414
Chicago
Yang, Wenying, Xiaohui Guo, Felipe Lauand, Lingyu Li, Hexin Fang, Qin Du, and Lei Kang. 2024. “Effects of Age and Disease Duration on the Efficacy and Safety of IGlarLixi in Asian People with Type 2 Diabetes: A Post Hoc Analysis of the LixiLan‐O‐AP and LixiLan‐L‐CN Trials.” Diabetes, Obesity & Metabolism 26 (4): 1197–1206. doi:10.1111/dom.15414.